ABSTRACT Stimulation of uric acid production by the well-known uricosuric drug probenecid was studied using potassium oxonate-treated rats and eviscerated rats sub jected to functional hepatectomy. In oxonate-treated rats, probenecid was hyperurico suric, increasing the glomerular-filtered amounts of uric acid and causing marked hyperuricemia. This could be completely blocked by combination dosing with allopur inol, an inhibitor of xanthine oxidase. In eviscerated rats subjected to functional hepatectomy, probenecid also increased plasma uric acid and urinary uric acid excretion, but when given together with allopurinol, the increase of plasma uric acid was abol ished with a remarkable increase of plasma hypoxanthine and xanthine. When pro benecid was given by combination dosing with propranolol, a beta adrenoceptor an tagonist, the hyperuricemia was also completely blocked. Thus, probenecid is con cluded to stimulate uric acid production, probably via some interaction with endoge nous catecholamine, resulting in hyperuricemia in rats, although it is a practical hypouricemic drug in humans.
Since probenecid was found to have urico suric activity by Wolfson et al. (1) , it has been used for medical treatment of hyperuricemia. Probenecid shows potent uricosuric activity in humans, but experimental results on its urico suric effects in non-human mammalia indicate that the effect is inconsistent (2-6). Species differences of uric acid metabolism and excre tion make it difficult to evaluate the uricosuric activity of probenecid. Among them, rats are known to show a net reabsorptive flux of uric acid in the renal tubules, like humans, though they handle uric acid by both renal excretion and hepatic metabolism, and therefore, have been sometimes utilized for evaluating urico suric drugs (7) . If their metabolic problems could be solved, they would be easier to use for studying uricosuric drugs than other animals with a net reabsorptive flux of uric acid in the renal tubules, such as chimpanzees and cebus monkeys.
Johnson et al. (8) have reported that potas sium oxonate is a useful inhibitor of uric acid metabolism in the liver. We have demon strated the utility of eviscerated rats subjected to functional hepatectomy for studying drug effects on extra-hepatic urate production (9) . In the present study, we applied these tech niques to evaluate the uricosuric activity of probenecid. It was definitely uricosuric, but also unexpectedly hyperuricemic in the rats. The paradoxical retention of uric acid induced by uricosuric agents has been explained as a consequence of reduction of UuaV resulting from bidirectional inhibition of uric acid trans port in the renal tubules. However, the pres ent communication clarified that probenecid is hyperuricemic in rats due to stimulation of uric acid production.
MATERIALS AND METHODS
Clearance study with potassium oxonate-treated rats
The-week-old male Wistar strain rats were used. They were cannulated into the femoral artery, femoral vein and bladder under anes thesia with pentobarbital. After administration of 60% urethane at 2 ml/kg, s.c., the rats were initially given 4% mannitol 1.7% potassium oxonate -1.5% inulin -0.9% sodium chloride solution, 6 ml/kg, as a bolus, then 4% mannitol 0.5% potassium oxonate -1.5% inulin 0.9% sodium chloride solution was in fused constantly at the flow rate of 0.05 ml/min on a hot plate at 30°C. After equilibration for 60 min with administration of 0.9% sodium chloride 4 ml/kg, i.p., at the midpoint, 0.2-ml blood samples were collected six times at 20-min intervals, and five 20-min urine samples were successively collected.
Probenecid and allopurinol were suspended in 1% gum arabic solution and administered intraperitoneally after the first urine collec tion.
Clearance study with eviscerated rats subjected to functional hepatectomy After the cannulation described above, functional hepatectomy was induced as pre viously described (9) . The animals were lapar otomized, and then their stomach, small and large intestines, pancreas, mesentery and spleen were removed after ligation and cutting of the coeliac artery with the anterior mesen teric artery, portal vein with the bile duct, esophagus and rectum. After stitching the abdomen, 5% glucose at 5 ml/kg was sub cutaneously administered; and then 4% man nitol -1.5% inulin 0.9% sodium chloride solution was intravenously infused at the flow rate of 0.05 ml/min on a hot plate at 30°C with intravenous administration of 6 ml/kg as a prime dosing. After equilibration for 30 min, 0.2 ml of blood was collected twice with a 60 min interval and a 60-min urine sample was obtained. Glucose administration was repeated at 60-min intervals to prevent hypoglycemia. Probenecid and pyrazinoic acid were dis solved in a diluted alkaline solution and neu tralized, and then administered intravenously at the beginning of urine collection. Allopur inol was suspended in 1% gum arabic solution and orally administered 60 min before the op eration. Propranolol was subcutaneously given just after the operation.
Determination of uric acid, hypoxanthine, xanthine and inulin
Uric acid in the plasma and urine were esti mated by the fluorometric method according to the procedure of Sumi et al. (10), while hypoxanthine and xanthine in the plasma and urine were measured by an HPLC method: a nucleosil 5C18 column (150 X 4.6 mm i.d.) was used with an eluent of 0.1 M NH4H2PO4 buffer adjusted to pH 4.1 at the flow rate of 1 ml/min. Monitoring was done at 254 nm. Inulin was estimated according to the method of Vurek and Pegram (11) .
In the clearance study with potassium oxonate-treated rats, the Pua value was adopted as the average of that at the begin ning and end of the urine collection.
Chemicals
All drugs used were commercial prepara tions: probenecid and allopurinol were pur chased from Sigma, pyrazinoic acid from Nacalai Tesque, and propranolol from Sumi tomo Kagaku.
Statistics
Data are shown as the mean and standard error. The significant difference from the con trol value in the clearance study using potas sium oxonate-treated rats was evaluated by Tukey's method, while that in the clearance study using eviscerated rats subjected to func tional hepatectomy was done by Student's t test.
RESULTS
Clearance study with potassium oxonate-treated rats As shown in Table 1 , the overall function of the rat kidneys treated with potassium oxonate remained unchanged during the 100-min clear ance experiment. The FEua value in the clear ance study was obviously under unity, indicat ing a net reabsorptive flux of uric acid in the renal tubules of the rats.
Probenecid, as shown in Table 2 , progres sively increased Pua and UuaV without any change of the FEua value. Both the hyper uricemic and hyperuricosuric effects were dose-dependent, and the hyperuricosuric effect was due to an increase in the Fua following elevation of Pua, because no change of the glomerular filtration rate could be found after the administration. The effects of allopurinol, a xanthine oxidase inhibitor, are shown in Table 3 . Allopurinol at 10 mg/kg, i.p., de creased Pua and UuaV with no effect on the renal handling of uric acid in the kidney, be cause the FEua value remained unchanged. As allopurinol also had no effect on the glo merular filtration rate, its hypouricosuric effect was caused by a decrease in the Fua due to the fall of Pua. The Pua value 60 min after administration of allopurinol decreased to half Table 1 .
Overall function of rat kidneys in intravenously oxonate-treated rats Data represent the mean ± S.E. of 9 rats. that of the pre-dosing one. These hypouricemic effects of allopurinol were observed dose-de pendently at more than 5 mg/kg, i.p. (data not shown). Under the combination dosing of allopurinol and probenecid, the hyperuricemic and hyperuricosuric effects of probenecid were completely blocked without any change of the FEua value (Table 3) .
Clearance study with eviscerated rats subjected to functional hepatectomy The effects of probenecid and pyrazinoic acid on Pua and UuaV in eviscerated rats sub jected to functional hepatectomy are shown in Table 4 . The Pua in the operated animals in creased slightly during the 60-min clearance study, indicating that the magnitude of ex trahepatic uric acid production might be great er than that of uric acid excretion. With admin istration of probenecid at 50 mg/kg, i.v., Pua during the clearance study increased marked ly, resulting in increased UuaV. However, pyrazinoic acid, an inhibitor of urate secretion in the renal tubules, caused a slight increase in Pua with reduction of UuaV. Thus, the in crease of Pua induced by probenecid was Data represent the mean ± S.E. The number of animals is given in parentheses. *, * * : Signifi cantly different from the level before drug administration at P < 0.05 and P < 0.01, respectively. Table 4 . Effects of probenecid and pyrazinoic acid on plasma uric acid and urinary uric acid excretion in eviscerated rats subjected to functional hepatectomy clearly different from that caused by pyrazi noic acid administration.
With combination dosing of probenecid and allopurinol, changes of uric acid, hypoxanthine and xanthine in the plasma and urine were studied. Figure 1 shows that allopurinol at 100 mg/kg, p.o., alone caused a marked decrease in Pua and UuaV, while probenecid had no effect on either when given in the combination dosing with allopurinol. Changes of PHx and Px and Ut-ixV and UxV are shown in Fig. 2 . Without allopurinol treatment, hypoxanthine and xanthine in the plasma and urine were be low the limit of detection (data not shown), while small amounts were found in the allopurinol-treated group. PHx and Px in creased considerably with combination dosing of probenecid and allopurinol. UHXV in creased to more than four-fold that of the allopurinol-treated rats following the elevation in plasma, although UxV remained un changed.
As shown in Table 5 , combination dosing of probenecid and propranolol was done in order to investigate the cause of probenecid-induced hyperuricemia and hyperuricosuria. The in crease of both Pua and UuaV by probenecid administration was completely blocked in the combination dosing with propranolol.
DISCUSSION
Probenecid has been used as a prominent hypouricemic drug in humans due to its potent uricosuric effect. However, because it shows bidirectional inhibition of urate transport in the renal tubules, like most uricosuric agents, it is known to induce a paradoxical retention of uric acid in clinical use (12, 13) . In such cases, the uric acid retention should be brought about by decreasing UuaV. Pyrazinoic acid is well known as a typical agent for caus ing the retention of uric acid by inhibiting tubular urate secretion. This study with rats showed that probenecid is both hyperuricemic and hyperuricosuric; it was markedly hyper uricemic in spite of causing an increase in UuaV. These results indicated that probenecid action on Pua elevation in rats occurs for reasons other than the reduction of UuaV.
Combination dosing with allopurinol, an in hibitor of xanthine oxidase, completely abol ished hyperuricemia induced by probenecid but not that by pyrazinoic acid (data not shown). Also, the probenecid-allopurinol com bination caused marked elevation of PHx and Px instead of Pua. This led to the conclusion that hyperuricemia induced by probenecid in rats is due to the stimulation of uric acid pro duction, at least, in the process prior to hypo xanthine production. Table 5 . Effect of propranolol on probenecid-induced hyperuricemia and hyperuri cosuria in eviscerated rats subjected to functional hepatectomy Probenecid at 50 mg/kg was intravenously administered at the beginning of the clearance experiment, while 0.5 mg/kg of propranolol was subcutaneously given 30 min before the probenecid administration. Data represent the mean and standard error. The number of animals is given in parentheses. * * : Significantly different from the non-treated value at P < 0.01.
We previously reported that a beta adre noceptor agonist isoproterenol produces marked hyperuricemia in eviscerated rats sub jected to functional hepatectomy resulting from stimulation of uric acid production, and this hyperuricemia can be completely blocked by propranolol (9) . In the present study, we presumed some relationship between endoge nous catecholamine and probenecid-induced hyperuricemia, because the marked increase of Pua after probenecid administration in rats was similar to the hyperuricemia induced by isoproterenol. In fact, probenecid-induced hyperuricemia and hyperuricosuria in the animals could also be blocked when proprano lol was given simultaneously, although pro pranolol alone had no effect on Pua in the ani mals as shown previously. Thus, endogenous catecholamine seems to have a role in the mechanism of probenecid-induced hyper uricemia in rats. To check this hypothesis, further studies are needed to show whether changes occur in endogenous catecholamine and adenine nucleotide metabolism after prob enecid administration.
The present experimental results reveal an adverse hyperuricemic property of probenecid, which is undesirable for a hypouricemic drug. Of course, since this was found using rats, we need to establish whether the findings are spe cific to rats or can be applied to humans. Although probenecid had no effect on the FEua value in rats, it is known to be uricosu ric in humans, causing an elevation of the FEua value. Therefore, even if probenecid causes stimulation of uric acid production in humans, any hyperuricemic effect might be masked by the hypouricemic effect due to the uricosuric action.
An acute gouty attack has been often observed during the normalization of urate pool size by probenecid therapy in hyper uricemic patients (13) , although the cause has not been clarified. Further study is needed from the viewpoint of stimulation of uric acid production. Also, the causes for the paradox ical retention of uric acid in probenecid thera py should be considered with regard to the stimulation of uric acid production. The pres ent study has shown that examination of probenecid-induced hyperuricemia in rats can lead to an alternative way of understanding the causes of unfavorable probenecid-induced effects.
